DRG Market Assessment 보고서

Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…

Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy is often unpredictable. Despite the need…

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…

Historically, metformin and the sulfonylureas were the most-prescribed drugs for type 2 diabetes. These agents dominated the early lines of therapy until disease progression required insulin…

Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options…

Diabetic macular edema (DME) occurs as a consequence of diabetes. It typically develops in the advanced stage of diabetic retinopathy and is characterized by leaking fluid from abnormal blood…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…

MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with severe asthma. Typical treatments for this…

Parkinson’s disease (PD) treatment is complex. The disease is heterogeneous, requiring individualized treatment and frequent adjustments to achieve symptom control. New therapies that address PD…

According to DRG epidemiology, more than 35 million people in the United States suffer migraines. Migraine prophylaxis, though underused, is a core treatment approach to reduce migraine frequency,…